Sarepta Therapeutics’ (SRPT) Underperform Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their underperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday,Benzinga reports.

Several other brokerages have also weighed in on SRPT. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Wolfe Research raised shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, July 9th. Finally, Benchmark reissued a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, September 9th. Eight equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and six have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $23.81.

Sarepta Therapeutics Trading Down 2.3%

Sarepta Therapeutics stock opened at $18.22 on Monday. Sarepta Therapeutics has a 12-month low of $14.68 and a 12-month high of $25.32. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62. The stock has a market capitalization of $1.92 billion, a PE ratio of -6.28, a price-to-earnings-growth ratio of 0.27 and a beta of 0.27. The firm has a 50 day simple moving average of $18.92 and a 200-day simple moving average of $18.80.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.22 by $0.42. The firm had revenue of $401.25 million for the quarter, compared to analysts’ expectations of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The firm’s quarterly revenue was down 34.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.02 earnings per share. As a group, equities research analysts expect that Sarepta Therapeutics will post 3.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently modified their holdings of the stock. Meeder Asset Management Inc. purchased a new position in Sarepta Therapeutics during the 2nd quarter valued at about $27,000. Nykredit A S purchased a new stake in shares of Sarepta Therapeutics in the second quarter worth approximately $43,000. Ancora Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the second quarter worth approximately $45,000. Hantz Financial Services Inc. boosted its holdings in shares of Sarepta Therapeutics by 348.3% during the fourth quarter. Hantz Financial Services Inc. now owns 2,784 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 2,163 shares during the period. Finally, Allworth Financial LP acquired a new stake in shares of Sarepta Therapeutics during the second quarter worth approximately $58,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. Its research platforms include RNA-based technologies, gene therapy and gene-editing approaches designed to address the underlying causes of genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for eligible patients with specific genetic mutations, as well as Elevidys, a gene therapy developed to treat certain patients with DMD.